Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Triptorelin

Hormonal & Reproductive

Molecular Dossier

  • Rank Index: 75
  • Status: FDA Approved
  • What does this mean?
  • Molecular Structure: MW: 1311.5 Da | Formula: C₆₄H₈₂N₁₈O₁₃ | CAS: 57773-63-4 | Sequence: pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂

About Triptorelin

Triptorelin (Decapeptyl, Trelstar) is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH), FDA-approved for prostate cancer, precocious puberty, and endometriosis. Like leuprorelin, continuous administration paradoxically suppresses the HPG axis via receptor downregulation, achieving castration-level testosterone within weeks. Unlike leuprorelin, triptorelin has attracted particular interest in the performance and longevity community as a one-time or short-course HPG axis restart agent. A single injection of triptorelin (100 mcg) can acutely stimulate LH and FSH release from the pituitary, which has been used experimentally to attempt HPG axis reinitiation following prolonged anabolic steroid use (post-cycle therapy). Several case reports and forum-documented protocols describe 100 mcg single-dose administration producing an LH surge that, in some hypogonadal subjects, appears to restart endogenous testosterone production. The scientific rationale involves resensitizing the pituitary after prolonged exogenous androgen suppression. Available as a long-acting 3-month or 6-month depot (Trelstar) for clinical use, or a short-acting daily injectable for specific protocols. The single-dose HPG restart use is off-label and not supported by randomized controlled trials. Adverse effects with sustained use include bone loss, hot flashes, and cardiovascular risks consistent with hypogonadism. The FDA-approved clinical indications are well-established, but the peptide community uses it for hormonal rescue purposes not formally studied.

Clinical Focus

GnRH Agonist — HPG Axis Restart, PCT, and Endocrine Reset

Archival Aliases

Decapeptyl, Trelstar, Diphereline, Gonapeptyl

Frequently Asked Questions

What makes triptorelin different from leuprorelin for PCT use?

Both are GnRH agonists that suppress the HPG axis with sustained use, but triptorelin is used experimentally in PCT as a single 100 mcg injection to produce an acute LH/FSH surge — the idea being one pulse to restart the pituitary rather than sustained suppression. Leuprorelin depots are long-acting by design and unsuitable for this purpose. Neither use in PCT is FDA-approved or supported by RCTs.

Is triptorelin legal to possess?

Triptorelin is prescription-only in most jurisdictions. It is not a controlled substance (not a scheduled drug) in the US, but dispensing requires a valid prescription. Research-grade sources are in a legal grey area similar to other research peptides.

How does triptorelin affect the HPG axis at the pituitary level?

Triptorelin binds GnRH receptors on pituitary gonadotrophs with higher affinity and longer duration than endogenous GnRH. A single acute dose floods these receptors and triggers an initial LH and FSH surge ("flare effect") lasting 24–72 hours. With continuous exposure, the receptors downregulate, leading to paradoxical suppression. The single-dose PCT strategy attempts to exploit only the initial flare without crossing into sustained suppression.

What are the safety concerns with off-label single-dose triptorelin use for PCT?

The primary risks of unsupervised single-dose triptorelin are dose accuracy (100 mcg is a small volume requiring precise measurement), contamination risk from non-pharmaceutical sources, and unpredictability of response — some users report supraphysiological LH spikes followed by temporary worsening of symptoms. Without baseline LH/FSH and testosterone labs before and after, it is impossible to assess response. No long-term safety data exists for this off-label application.

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: 1311.5 Da | Formula: C₆₄H₈₂N₁₈O₁₃ | CAS: 57773-63-4 | Sequence: pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂
Primary Pathway Hormonal & Reproductive
Research Phase FDA Approved

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] pubmed.ncbi.nlm.nih.gov
[REF 3] pubmed.ncbi.nlm.nih.gov

Data Verified: 2026-05-15

Synergistic Matrix